AU2020279395B2 - Formulations of terlipressin - Google Patents

Formulations of terlipressin

Info

Publication number
AU2020279395B2
AU2020279395B2 AU2020279395A AU2020279395A AU2020279395B2 AU 2020279395 B2 AU2020279395 B2 AU 2020279395B2 AU 2020279395 A AU2020279395 A AU 2020279395A AU 2020279395 A AU2020279395 A AU 2020279395A AU 2020279395 B2 AU2020279395 B2 AU 2020279395B2
Authority
AU
Australia
Prior art keywords
composition
terlipressin
months
kit
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020279395A
Other languages
English (en)
Other versions
AU2020279395A1 (en
Inventor
Jonathan Adams
Jorge BACARDIT CABADO
Penelope MARKHAM
Denise Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovie Inc
Original Assignee
Biovie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovie Inc filed Critical Biovie Inc
Publication of AU2020279395A1 publication Critical patent/AU2020279395A1/en
Application granted granted Critical
Publication of AU2020279395B2 publication Critical patent/AU2020279395B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/002—Packages specially adapted therefor, e.g. packages for syringes or needles or kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020279395A 2019-05-22 2020-05-22 Formulations of terlipressin Active AU2020279395B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851366P 2019-05-22 2019-05-22
US62/851,366 2019-05-22
PCT/US2020/034269 WO2020237170A1 (en) 2019-05-22 2020-05-22 Formulations of terlipressin

Publications (2)

Publication Number Publication Date
AU2020279395A1 AU2020279395A1 (en) 2021-12-16
AU2020279395B2 true AU2020279395B2 (en) 2025-08-28

Family

ID=73458147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020279395A Active AU2020279395B2 (en) 2019-05-22 2020-05-22 Formulations of terlipressin

Country Status (11)

Country Link
US (3) US12156898B2 (cg-RX-API-DMAC7.html)
EP (1) EP3972628A4 (cg-RX-API-DMAC7.html)
JP (1) JP7579811B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220011697A (cg-RX-API-DMAC7.html)
CN (1) CN114096267B (cg-RX-API-DMAC7.html)
AU (1) AU2020279395B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023274A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141488A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003065A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014310A (cg-RX-API-DMAC7.html)
WO (1) WO2020237170A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103215A1 (en) 2018-06-15 2019-12-19 Ferring B.V. Terlipressin compositions and uses thereof
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome
CN115856149B (zh) * 2022-12-26 2023-12-05 哈尔滨吉象隆生物技术有限公司 一种特利加压素中杂质的检测方法
CN118121553A (zh) * 2024-01-29 2024-06-04 陕西天宇制药有限公司 特利加压素冻干粉及其制备方法
CN121779506B (zh) * 2026-01-05 2026-07-31 天津市药品检验研究院 一种特利加压素与甘露醇的酯化杂质及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237508A1 (en) * 2008-09-09 2011-09-29 Rijksuniversiteit Groningen Peptide Formulations and Uses Thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20040153032A1 (en) * 2002-04-23 2004-08-05 Garribotto John T. Dispenser for patient infusion device
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
PL377761A1 (pl) * 2003-01-09 2006-02-20 Baxter Healthcare S.A. Bezpieczny pojemnik do substancji biologicznie czynnych i sposób jego wytwarzania
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
WO2007144768A2 (en) 2006-02-13 2007-12-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
EP2167040A1 (en) 2007-06-07 2010-03-31 MDRNA, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
EP2175874A2 (en) 2007-08-14 2010-04-21 Ferring B.V. Use of peptidic vasopressin receptor agonists
US20100311642A1 (en) 2007-09-28 2010-12-09 Ferring B.V. Use of v2 receptor antagonists in combination with vaso pressinergic agnosts
WO2009062174A1 (en) 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
CA2739077A1 (en) 2008-10-20 2010-04-29 Robert K. Hickman Antibodies that bind to il-18 and methods of purifying the same
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
MX355507B (es) 2009-03-09 2018-04-19 Bioatla Llc Proteinas mirac.
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
US8958358B2 (en) * 2009-06-24 2015-02-17 Nokia Siemens Networks Oy Network element for changing the timeslot type according to the received information
US8613892B2 (en) * 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
CN102440957B (zh) 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CA2891281C (en) 2012-11-12 2023-11-28 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
CN105592855A (zh) 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US20150056194A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
US20150328317A1 (en) 2014-05-13 2015-11-19 Eagle Pharmaceuticals, Inc. Aqueous buffer-free bivalirudin compositions
US20200046798A1 (en) 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20200237856A1 (en) 2014-10-24 2020-07-30 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
AU2015335855A1 (en) 2014-10-24 2017-05-18 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
WO2017150824A1 (ko) 2016-03-03 2017-09-08 가천대학교 산학협력단 마이크로 니들 및 이의 제조방법
JP2019516679A (ja) * 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 生物活性剤に関する方法および組成物
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
US11318183B2 (en) 2018-03-20 2022-05-03 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
CA3103215A1 (en) 2018-06-15 2019-12-19 Ferring B.V. Terlipressin compositions and uses thereof
CN108659104B (zh) 2018-07-03 2020-06-09 北京市新里程医药科技有限公司 一种特利加压素的制备方法及其药物组合物
CN109010795B (zh) 2018-09-12 2021-10-22 南京康舟医药科技有限公司 醋酸特利加压素注射液以及其制备方法
EP3897571A1 (en) 2018-12-21 2021-10-27 Arecor Limited Novel composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110237508A1 (en) * 2008-09-09 2011-09-29 Rijksuniversiteit Groningen Peptide Formulations and Uses Thereof

Also Published As

Publication number Publication date
CL2021003065A1 (es) 2023-01-06
JP7579811B2 (ja) 2024-11-08
BR112021023274A2 (pt) 2022-03-08
MX2021014310A (es) 2022-01-26
EP3972628A1 (en) 2022-03-30
EP3972628A4 (en) 2023-01-18
CN114096267A (zh) 2022-02-25
KR20220011697A (ko) 2022-01-28
AU2020279395A1 (en) 2021-12-16
US12156898B2 (en) 2024-12-03
CA3141488A1 (en) 2020-11-26
US20220233634A1 (en) 2022-07-28
WO2020237170A1 (en) 2020-11-26
US20220202907A1 (en) 2022-06-30
JP2022533759A (ja) 2022-07-25
CN114096267B (zh) 2025-03-18
US20250249066A1 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
US20250249066A1 (en) Formulations of Terlipressin
AU2004237982B2 (en) Liquid stabilized protein formulations in coated pharmaceutical containers
EP3253391B1 (en) Aqueous solution formulations of vancomycin
AU2016326749B2 (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP2995298B1 (en) Stabilized pemetrexed preparation
EP3536380A1 (en) Rapid-acting insulin compositions
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
US20200188478A1 (en) Pre-mixed, ready to use vancomycin compositions
EP2922530B1 (en) Caspofungin acetate formulations
US20210128507A1 (en) Formulation for use in a method of treatment of pain
EP3679925B1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
ES3059242T3 (en) Ephedrine liquid formulations
US20250325476A1 (en) Stable intravenous diltiazem hydrochloride formulation and use thereof
WO2022034545A1 (en) Etelcalcetide formulations for parenteral use
WO2021048748A1 (en) Pharmaceutical formulations comprising diclofenac
HK40033919A (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40033919B (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40033882A (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK1215668B (en) Caspofungin acetate formulations
HK1233954B (zh) 可注射布洛芬制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)